Bibliography
- Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-18
- Sabino-Silva R, Mori RC, David-Silva A, et al. The Na+/glucose cotransporters: from genes to therapy. Braz J Med Biol Res 2010;43:1019-26
- Freitas HS, Anhê GF, Melo KF, et al. Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008;149:717-24
- da Silva AS, Dias LD, Borges JF, et al. Renal GLUT1 reduction depends on angiotensin-converting enzyme inhibition in diabetic hypertensive rats. Life Sci 2013;92:1174-9
- Wright EM, Turk E, Martin MG. Molecular basis for glucose-galactose malabsorption. Cell Biochem Biophys 2002;36:115-21
- Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5(1):133-41
- Freitas HS, D'Agord Schaan B, da Silva RS, et al. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats. Nephron Physiol 2007;105:42-51
- Boyle LD, Wilding JP. Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. Expert Opin Emerg Drugs 2013;18:375-91
- FDA Advisory Committee Meeting. FDA Briefing Document. NDA 202293 (Dapagliflozin Tablets, 5 mg and 10 mg. Sponsor: Bristol–Myers Squibb). 2011. Available from: http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/ucm262994.pdf [Accessed 3 September 2013]
- FDA Advisory Committee Meeting. FDA Briefing Document. NDA 204042 (Invokana (canagliflozin) Tablets. Applicant: Janssen Pharmaceuticals, Inc.). 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM334550.pdf [Accessed 3 September 2013]
- Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-93
- Demaris KM, White JR. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2013;49:289-301
- Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012;92:158-69
- Devenny JJ, Godonis HE, Harvey SJ, et al. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia. Obesity 2012;20:1645-52
- Donders GG. Lower genital tract infections in diabetic women. Curr Infect Dis Rep 2002;4:536-9
- Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159:262-74
- Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
- Ly JP, Onay T, Sison K, et al. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 2011;22:113-23
- Abdul-Ghani MA, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 2013;62:3324-8
- Marks J, Carvou NJ, Debnam ES, et al. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 2003;553(Pt 1):137-45
- Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61